Amyris, Inc. (NASDAQ:AMRS) announced that it has entered into a product development and production agreement for a new class of human nutrition ingredients with Koninklijke DSM N.V., the global science-based company active in health, nutrition and materials. With this latest agreement, Amyris and DSM have now executed several key partnership agreements focused on developing and producing solutions that serve large markets within the animal and human health and nutrition segments.
DSM is partnering with Amyris to fund development of the technology to produce critical ingredients on a cost-effective basis utilizing Amyris’s capabilities coupled with DSM’s sustainability-focused business model and brand recognition. DSM will commercialize innovative new human nutrition solutions incorporating these ingredients utilizing its robust global sales and marketing channel. The partnership announced today is focused on developing the ingredient for market introduction in 2019.
“Our partnership with DSM will allow us to introduce a new generation of ingredients targeted for human nutrition,” said John Melo, President and CEO of Amyris. “With this development, we are working toward fulfilling our mission, providing consumers with sustainably-sourced, healthy and nutritious products. Our product and production platform will create a unique position and broadened access for a number of critical ingredients. DSM’s market leadership in many areas, including in human health and nutrition, complements the broad technical capabilities Amyris has built to date. This collaboration includes a material initial payment and will result in significant medium term product revenue.”
“Our collaboration with DSM, a leader in human health and nutrition, will result in an ability to deliver human nutrition solutions, resulting in improved human health and well-being,” said Cindy Bryant, Senior Vice President and Head of Collaborations at Amyris.
Shares of Amyris are currently trading at $3.38, up $0.06 or 1.81%. AMRS has a 1-year high of $18.15 and a 1-year low of $1.86. The stock’s 50-day moving average is $2.92 and its 200-day moving average is $2.11.
On the ratings front, AMRS stock has been the subject of a number of recent research reports. In a report issued on September 26, H.C. Wainwright analyst Amit Dayal reiterated a Buy rating on AMRS, with a price target of $15, which represents a potential upside of 352% from where the stock is currently trading. Separately, on September 18, Cowen’s Jeff Osborne reiterated a Hold rating on the stock and has a price target of $3.50.
According to TipRanks.com, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Amit Dayal and Jeff Osborne have a yearly average loss of -0.1% and a return of 5.1% respectively. Dayal has a success rate of 42% and is ranked #3440 out of 4699 analysts, while Osborne has a success rate of 52% and is ranked #915.
Amyris engages in the research, development, manufacture, and sale of fuels and farnesene-derived products. Its products include cosmetics, flavors and fragrances, performance materials, diesel, jet fuel, and lubricants.